Analysis for DGX

📈 Growth & Financial Trajectory

Over 8 quarters, revenues rose from about $2.49B to $3.04B, a gain of roughly 22%. Net income rose from about $226M–$237M in late 2024 to $334M in Q2 2026, signaling sustained earnings expansion as scale increases. The trajectory remains positive with a consistent quarter-over-quarter rise in both top- and bottom-line figures.

💰 Margins & Cash Flow

Gross margins hovered in the low-to-mid 30s (roughly 32–34%) across the period, with Q2 2026 showing expansion to about 33.7%. Operating leverage is evident as revenues grow with stable opex, and net operating cash flow rose to the high hundreds of millions, e.g., Net Cash Flow From Operating Activities around $597M in 2026 Q2. Free cash flow remains positive, while investing and financing cash flows are more variable by quarter.

🛡️ Balance Sheet & Liquidity

The balance sheet remains solid: assets around $16–17B, liabilities near $9B, and equity about $6.8–7.8B. Long-term debt sits around $5.6–6.0B, with current assets exceeding current liabilities, supporting liquidity and resilience.

⚠️ Key Drivers & Risks

• Drivers: Strong demand for diagnostic services and a scalable lab network; favorable utilization and pricing dynamics.
• Risks: Regulatory reimbursement shifts; cycle-related variability and competition could pressure margins or multiple.